首页>投融资
TRexBio
B轮
TRex Bio is a biotechnology company focused on the development of therapies for the potential treatment of immune-mediated diseases.In March 2022, the company completed a USD 26 million extension of its Series A financing in a round led by new investor Polaris Partners. This brings the total Series A funding raised to USD 85 million. Laurion Capital, and all the existing TRexBio institutional shareholders participated in the latest round including founding investor SV Health Investors, Eli Lilly, Johnson & Johnson Innovation JJDC, Pfizer Ventures and Alexandria Venture Investments.In June 2021, TRex Bio announced the closing of the final tranche of a $59 million Series A financing
基本信息
-
公司全称TRex Bio Inc
-
类型免疫疗法研发商
-
产业领域医药研发/制造、化学&生物药
-
公司人数15~50人
-
地址681 Gateway Blvd 4Th Floor SOUTH SAN FRANCISCO CALIFORNIA 94080; US;
-
联系电话650-567-5582
-
邮箱info@trex.bio
-
成立时间2018-01-01
投融资
-
2024-11-13B轮8400万美元Delos CapitalAvego Bioscience CapitalAgent CapitalEli LillySV Health Investors辉瑞Johnson & Johnson InnovationAlexandria Venture InvestmentsPolaris Partners
-
2022-03-08A轮2600万美元辉瑞Alexandria Venture InvestmentsJohnson & Johnson Development CorporationPolaris PartnersLaurion Capital ManagementSV Health InvestorsEli Lilly
-
2021-06-22A轮5900万美元Eli LillyJohnson & Johnson InnovationAlexandria Venture Investments辉瑞SV Health Investors
相关投融资企业
A轮
Ouro Medicines是一家免疫重置公司，通过结合科学专业知识、通过临床推进细胞耗竭疗法的跟踪记录以及强大的管道来正面应对慢性免疫介导的疾病。Ouro最领先的候选产品是OM336，这是一种最近从康诺亚生物获得许可的BCMA靶向的双特异性TCE。
A轮
RhyGaze开发一种新的基因疗法，旨在恢复患者的视力。该公司的治疗技术将光传感器基因专门传递给失去光敏感性的视锥细胞，并修复其检测光的能力，使医疗保健行业能够为失明患者提供视力恢复。
未公开
Thetis Pharmaceuticals LLC is a pharmaceutical company focused on the development of prescription drugs for diabetes, hypertriglyceridemia and dyslipidemia. Thetis's proprietary HEALER technology (High Efficiency Amino Lipid Enabled Release) uses transformative ionic chemistry to revitalize proven therapeutic agents and generated solid, stable APIs.In July 2021, Thetis Pharmaceuticals LLC announced the launch of a new program in cancer TP-317, which is a Resolvin E1 therapy for the treatment of solid tumour cancers published in the Journal of Experimental Medicine.In May 2013, the company raised $5.7 million through a series A financing.In September 2011, Thetis secured first round funding. At that time, the company planned to secure additional capital in the second half of 2012
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息